Please login to the form below
Cerdelga
This page shows the latest Cerdelga news and features for those working in and with pharma, biotech and healthcare.
R&D productivity takes off
Among these, notable examples include PTC Therapeutics' Translarna (ataluren) - the first medicine approved for the treatment of Duchenne muscular dystrophy (DMD) - and Sanofi/Genzyme's Cerdelga (eliglustat) for Gaucher disease, a
Latest news
-
Genzyme's oral Gaucher drug cleared in Europe
In contrast, Cerdelga and Zavesca are glucosylceramide synthase inhibitors, which work by reducing the substrate for the deficient enzyme. ... Analysts have suggested Cerdelga could achieve sales upwards of $350m in 2017 and eventually rival Cerezyme in
-
Orphan drugs in latest CHMP recommendations
advisers. The Committee for Medicinal Products for Human Use (CHMP) backed Genzyme's Cerdelga (eliglustat) and Boehringer Ingelheim's Ofev (nintedanib) in its latest round of opinions - which are usually followed ... Cerdelga has demonstrated it is as
-
Sanofi plans 18 new product launches by 2020
The remainder of its growth portfolio are Cerdelga (eliglustat) for Gaucher disease - the only approved oral, first-line therapy for the rare genetic disease, Lemtrada (alemtuzumab) for multiple sclerosis and sarilumab,
-
FDA gives green light to Genzyme’s oral Gaucher drug
the possibility that Cerdelga could be used alongside Cerezyme as a combination regimen. ... The company said it wants a pricing strategy that does not drive patients towards either Cerezyme or Cerdelga, making the choice of therapy a purely clinical
More from news
Approximately 2 fully matching, plus 3 partially matching documents found.
Latest Intelligence
-
Deal Watch table for November 2014
Cerdelga (eliglustat) sold by Vertex. Acquisition 75% royalty stream. 66. Five Prime Therapeutics / BMS.
-
Pharma deals during November 2014
In another similar deal, PDL Biopharma acquired the 75% of the University of Michigan's worldwide royalty interest in Cerdelga (eliglustat) for $66m. ... Cerdelga, an oral therapy for adult patients with Gaucher disease type 1, was developed by Genzyme
More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.
Featured jobs
- Account Manager – Healthcare advertising
-
Salary TBC
-
Senior Medical Writer
-
Competitive salary plus benefits
- Client Services Director- Flexible Working
-
Negotiable
-
Events Executive
-
DOE
- Account Manager, Healthcare Communications
-
£32, 000 - £40, 000 bonus benefits
-
Account Director – UK Office
-
Excellent salary and benefits
Subscribe to our email news alerts
- Novartis eyes potential new indication for Cosentyx
- J&J's Tremfya filed for approval in US for psoriatic arthritis
- AbbVie/Allergan's merger faces public opposition
- Envision Pharma Group relocates to support expansion
- Biogen loses another pipeline drug to toxicity concerns
- AZ, Merck’s Lynparza scores market-expanding clinical success
- Report: Customer experience, shaping digital healthcare
- The benefits of uniting in a divergent environment
- Encouraging signs in biomarker R&D
- J&J puts pressure on rivals with new Erleada okay in prostate cancer
- Pharma exhibition stand design with added value
- Bluebird Bio reveals further encouraging data for CALD gene therapy
PMHub
SEVEN STONES
Seven Stones is a creative, independent healthcare communications agency of movers and thinkers. We've been doing health differently since 1991....
Latest intelligence
- Report: Customer experience, shaping digital healthcare
- In this issue of ‘Perspective’ we speak with industry experts to learn about the world of digital healthcare, and how pharma is beginning to utilise these modern technologies to enhance...
- Encouraging signs in biomarker R&D
- The cancer immunotherapy firms ramping-up biomarker R&D...
- Programmatic methodology and why you should be using it
- What is it? How does it work? Why is everyone talking about it? By Richard Webb - Associate Director...
Quick links
Infographics
